{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:10:54Z","timestamp":1793077854229,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110899","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:21:22Z","timestamp":1745086882000},"page":"110899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-6033","authenticated-orcid":false,"given":"Jesper Grau","family":"Eriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-2082","authenticated-orcid":false,"given":"Christian","family":"Maare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-3929","authenticated-orcid":false,"given":"J\u00f8rgen","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Bratland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-0161","authenticated-orcid":false,"given":"Claus Andrup","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-3193","authenticated-orcid":false,"given":"Jan","family":"Alsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110899_b0005","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1200\/JCO.1993.11.10.1873","article-title":"Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer","volume":"11","author":"Dassonville","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0010","first-page":"2884","article-title":"Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas","volume":"5","author":"Akimoto","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110899_b0015","first-page":"701","article-title":"In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody","volume":"6","author":"Milas","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110899_b0020","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based the","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110899_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijrobp.2022.12.015","article-title":"Long-term update of NRG\/RTOG 0522: A randomized phase 3 trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer","volume":"116","author":"Caudell","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110899_b0040","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.4049\/jimmunol.173.7.4699","article-title":"Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy","volume":"173","author":"Bleeker","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2025.110899_b0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.radonc.2007.06.007","article-title":"Phase I\/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck","volume":"85","author":"Bastholt","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2012.09.017","article-title":"Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression","volume":"105","author":"Lassen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bmj.330.7495.843","article-title":"Treatment allocation by minimisation","volume":"330","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.110899_b0060","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/0284186X.2019.1658897","article-title":"A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma","volume":"58","author":"Saks\u00f8","year":"2019","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.radonc.2025.110899_b0065","article-title":"Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial. Submitted to","author":"Hansen","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.radonc.2014.11.032","article-title":"Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer","volume":"113","author":"Lassen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0075","doi-asserted-by":"crossref","unstructured":"Mes\u00eda R, Henke M, Fortin A, Minn H, Cesar A, Ancona Y, et al. Chemoradiotherapy with or without panitumumab in patients with unresected , locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised , controlled , open-label phase 2 trial 2018;16:208\u201320.","DOI":"10.1016\/S1470-2045(14)71198-2"},{"key":"10.1016\/j.radonc.2025.110899_b0080","doi-asserted-by":"crossref","first-page":"102371","DOI":"10.18632\/oncotarget.21987","article-title":"The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: A meta-analysis of randomized trials","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2025.110899_b0085","first-page":"4637","article-title":"Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on well-established A431 cell xenografts","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.110899_b0090","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.110899_b0095","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.radonc.2025.110899_b0100","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.radonc.2013.08.036","article-title":"Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials","volume":"108","author":"Lassen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0110","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","article-title":"Association of human Papillomavirus and p16 status with outcomes in the IMCL-9815 Phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without C","volume":"34","author":"Rosenthal","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0115","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1080\/0284186X.2023.2266127","article-title":"HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study","volume":"62","author":"Lilja-Fischer","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"HNCIG-EPIC group. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110899_b0125","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/0284186X.2018.1464664","article-title":"Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial","volume":"57","author":"Br\u00f8ndum","year":"2018","journal-title":"Acta Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402500194X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402500194X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:57:44Z","timestamp":1753775864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402500194X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"alternative-id":["S016781402500194X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110899","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110899"}}